MetLife Investment Management’s Capricor Therapeutics CAPR Stock Holding History

MetLife Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$756K	Buy	31,380 +8,185	+35%	+$248K	﹤0.01%	1672
2026 Q1	$705K	Buy	23,195 +1,219	+6%	+$32.5K	﹤0.01%	1582
2025 Q4	$634K	Buy	21,976 +7,740	+54%	+$101K	﹤0.01%	1680
2025 Q3	$103K	Sell	14,236 -8,006	-36%	-$58.9K	﹤0.01%	2641
2025 Q2	$221K	Hold	22,242	–	–	﹤0.01%	2139
2025 Q1	$211K	Sell	22,242 -444	-2%	-$6.16K	﹤0.01%	2171
2024 Q4	$313K	Buy	+22,686	New	+$398K	﹤0.01%	2048

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MetLife Investment Management's CAPR Position: Q2 2026 in Review

MetLife Investment Management increased its Capricor Therapeutics (CAPR) stake by 35% in Q2 2026, buying an estimated $248K and bringing the position to 31,380 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

MetLife Investment Management first reported a position in CAPR in Q4 2024 and has held it in 7 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

MetLife Investment Management held 31,380 shares of Capricor Therapeutics worth $756K as of Q2 2026.
MetLife Investment Management bought 8,185 Capricor Therapeutics shares in Q2 2026, an estimated $248K.
Capricor Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1672 holding.
MetLife Investment Management first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 7 quarters since.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.